ストックスクリーナーアプリを入手
7.56
8.46%
0.59
アフターアワーズ：
7.41
-0.15
-1.98%
前日終値:
$6.97
開ける：
$6.98
24時間の取引高:
2.10M
Relative Volume:
1.50
時価総額：
$624.25M
収益：
-
当期純損益:
$-314.85M
株価収益率:
-2.1103
EPS:
-3.5825
ネットキャッシュフロー:
$-283.27M
1週間 パフォーマンス:
+11.83%
1か月 パフォーマンス:
-7.80%
6か月 パフォーマンス:
+86.67%
1年 パフォーマンス:
-29.28%
1日の値動き範囲:
$6.915
$7.56
1週間の範囲:
$6.50
$7.56
52週間の値動き範囲:
$2.68
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Compare REPL vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
7.56 | 575.53M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-10-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-09-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-30 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | ダウングレード | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-23 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-06-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-04-17 | 再開されました | Piper Sandler | Overweight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-17 | 開始されました | BTIG Research | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2020-10-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-09-04 | 開始されました | ROTH Capital | Buy |
| 2019-07-23 | 開始されました | Chardan Capital Markets | Buy |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-25 | 開始されました | Wedbush | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 開始されました | JP Morgan | Overweight |
| 2018-08-14 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Replimune Group Inc (REPL) 最新ニュース
Replimune's Oncolytic Viral Therapy For Melanoma Faces Second Shot At FDA Approval - RTTNews
Replimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma Therapy - MSN
Aug PostEarnings: Does Replimune Group Inc align with a passive investing strategyWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect? - MSN
Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat
Institutional Investors Double Down on Replimune Amid Market Turmoil () - aktiencheck.de
Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Down 8%Here's What Happened - MarketBeat
Wedbush Upgrades Replimune Group (REPL) - MSN
Replimune Group (NASDAQ:REPL) Trading 11.1% HigherHere's Why - MarketBeat
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Replimune Stock Quote, Share Price, News and Analysis - Longbridge
REPL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Finviz
Replimune to Present at Two Upcoming Investor Conferences - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat
Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group, Inc. (REPL) Stock Analysis: A High-Potential Biotech Play with 67% Upside - DirectorsTalk Interviews
Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us
Replimune's Pivotal FDA Verdict Approaches - AD HOC NEWS
Market Leaders: Can Replimune Group Inc expand its profit margins2025 Fundamental Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Analyst Calls: Is Apyx Medical Corporation in accumulation or distribution phaseEarnings Miss & Real-Time Volume Analysis - baoquankhu1.vn
Replimune Shares Approach a Pivotal Regulatory Milestone - AD HOC NEWS
Replimune Group, Inc. (REPL) Stock Analysis: Unpacking a 50% Potential Upside in Biotechnology - DirectorsTalk Interviews
Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha
What is Replimune Group Inc.’s market positionQuarterly Profit Summary & Precise Swing Trade Entry Alerts - mfd.ru
Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan
Institutional Confidence Surges in Replimune as Key Drug Review Looms - AD HOC NEWS
Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP - MarketBeat
Replimune rebounds despite analyst downgrades on FDA rejection - MSN
Forbion discloses 3.5% Replimune (REPL) stake in ownership filing - Stock Titan
REPL SEC FilingsReplimune Group 10-K, 10-Q, 8-K Forms - Stock Titan
How Replimune Group Inc. stock reacts to job market dataWeekly Trade Analysis & Risk Controlled Stock Pick Alerts - mfd.ru
Will Replimune Group Inc. stock outperform tech sector in 20252025 Fundamental Recap & Low Risk Entry Point Guides - mfd.ru
Can Replimune Group Inc. be recession proofJuly 2025 Big Picture & High Conviction Investment Ideas - mfd.ru
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know - Finviz
Buybacks Report: Can Replimune Group Inc expand its profit marginsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is now the right time to enter Replimune Group Inc.Analyst Downgrade & Verified Entry Point Signals - mfd.ru
Insider Sell: Is Replimune Group Inc stock undervalued right now2025 Market Outlook & Daily Growth Stock Investment Tips - baoquankhu1.vn
Why Replimune Group Inc. stock is favored by pension fundsJuly 2025 Momentum & Entry Point Confirmation Signals - mfd.ru
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st
Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00 - MarketBeat
Piper Sandler Maintains 'Overweight' Rating for REPL, Raises PT to $14 | REPL Stock News - GuruFocus
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Replimune Secures Financial Runway Through 2027 - AD HOC NEWS
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Replimune Group Inc (REPL) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):